-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Braxia Opens New Clinic in Ontario, Facilitating Further Access To Ketamine And Psilocybin Treatments
Braxia Opens New Clinic in Ontario, Facilitating Further Access To Ketamine And Psilocybin Treatments
Braxia Scientific Corp. (CSE:BRAX) (OTC:BRAXF), a medical research company with clinics that provide innovative treatments for people suffering from major depressive disorder and related mental health conditions, has opened a new health clinic in the Kitchener-Waterloo area in Ontario, CA, which represents the fifth location the company has in that country.
As well as providing treatment for mental health disorders through Braxia-owned multidisciplinary clinics, the company is also involved in research related to the discovery and commercialization of novel drugs and delivery methods.
More specifically, Braxia seeks to develop ketamine and derivatives and other psychedelic products from its IP platform. Through its wholly-owned subsidiary, the Canadian Rapid Treatment Center of Excellence Inc., Braxia operates community-based clinics offering rapid-acting treatments like intravenous (IV) and oral ketamine, and psilocybin for treatment-resistant depression (TRD) and other mental health disorders.
Clinics are located in Mississauga, Toronto, Kitchener-Waterloo, Ottawa and Montreal. Their patient experience delivery is built around global best practices guidelines led by depression researchers Dr. McIntrye and Dr. Rosenblat in the American Journal of Psychiatry.
In response to the increased demand for these kinds of therapies resulting from the COVID-19 pandemic, the company plans to expand by establishing new clinics in Toronto and Ottawa.
In this respect, Braxia's VP of operations Kevin Kratiuk added, "While Braxia has been managing the patient volumes to date and ensuring care is delivered in a timely manner, an infrastructure expansion was needed to better support our communities and address the unmet burden of treatment-resistant depression. With our new clinic and future expansion plans for our existing clinics, we will also offer more convenient access to treatment for new and existing patients."
Among other studies led by the company, they are currently conducting a Phase 2 multi-dose psilocybin clinical trial for the treatment of resistant depression, which has reported positive preliminary results so far.
The ongoing trial is the first approved multi-dose psilocybin trial in Canada. Its results, together with the Health Canada special access program (SAP), are enabling psilocybin to be prescribed by physicians on a case-by-case basis to patients in need. To date, Braxia has treated patients with psilocybin through its ongoing multi-dose clinical trial and trained 20 therapists via the Braxia Institute for psilocybin-assisted therapy.
Braxia Scientific Corp. (CSE:BRAX) (OTC:BRAXF), a medical research company with clinics that provide innovative treatments for people suffering from major depressive disorder and related mental health conditions, has opened a new health clinic in the Kitchener-Waterloo area in Ontario, CA, which represents the fifth location the company has in that country.
布拉夏科學公司(CSE:BRAX)(場外交易代碼:BRAXF),一家醫學研究公司開設了一家診所,為患有嚴重抑鬱障礙和相關心理健康問題的人提供創新治療,該公司在紐約開設了一家新的健康診所。加利福尼亞州安大略省的基奇納-滑鐵盧地區,這是該公司在中國擁有的第五個門店。
As well as providing treatment for mental health disorders through Braxia-owned multidisciplinary clinics, the company is also involved in research related to the discovery and commercialization of novel drugs and delivery methods.
除了通過布拉夏擁有的多學科診所提供精神健康障礙的治療外,該公司還參與了與新藥和給藥方法的發現和商業化相關的研究。
More specifically, Braxia seeks to develop ketamine and derivatives and other psychedelic products from its IP platform. Through its wholly-owned subsidiary, the Canadian Rapid Treatment Center of Excellence Inc., Braxia operates community-based clinics offering rapid-acting treatments like intravenous (IV) and oral ketamine, and psilocybin for treatment-resistant depression (TRD) and other mental health disorders.
更具體地説,Braxia尋求從其知識產權平臺開發氯胺酮及其衍生物和其他迷幻產品。通過其全資子公司,加拿大卓越快速治療中心有限公司。,Braxia.經營社區診所,提供速效治療,如靜脈注射和口服氯胺酮,以及裸蓋菇素治療難治性抑鬱症(TRD)和其他精神健康疾病。
Clinics are located in Mississauga, Toronto, Kitchener-Waterloo, Ottawa and Montreal. Their patient experience delivery is built around global best practices guidelines led by depression researchers Dr. McIntrye and Dr. Rosenblat in the American Journal of Psychiatry.
診所位於密西索加、多倫多、基奇納-滑鐵盧、渥太華和蒙特利爾。他們的患者體驗交付是圍繞由抑鬱症研究人員領導的全球最佳實踐指南構建的McIntrye博士和羅森布拉特博士在美國精神病學雜誌.
In response to the increased demand for these kinds of therapies resulting from the COVID-19 pandemic, the company plans to expand by establishing new clinics in Toronto and Ottawa.
為了應對新冠肺炎疫情導致的對這類療法的需求增加,該公司計劃通過在多倫多和渥太華建立新的診所來擴大規模。
In this respect, Braxia's VP of operations Kevin Kratiuk added, "While Braxia has been managing the patient volumes to date and ensuring care is delivered in a timely manner, an infrastructure expansion was needed to better support our communities and address the unmet burden of treatment-resistant depression. With our new clinic and future expansion plans for our existing clinics, we will also offer more convenient access to treatment for new and existing patients."
在這方面,布拉夏運營副總裁凱文·克拉蒂烏克他補充道:“雖然Bracia到目前為止一直在管理患者數量並確保及時提供護理,但需要擴大基礎設施,以更好地支持我們的社區,解決難治性抑鬱症尚未滿足的負擔。通過我們新的診所和我們現有診所的未來擴展計劃,我們還將為新患者和現有患者提供更方便的治療途徑。”
Among other studies led by the company, they are currently conducting a Phase 2 multi-dose psilocybin clinical trial for the treatment of resistant depression, which has reported positive preliminary results so far.
在該公司領導的其他研究中,他們目前正在進行一項裸蓋菇素多劑量2期臨牀試驗用於治療難治性抑鬱症,到目前為止已經報告了積極的初步結果。
The ongoing trial is the first approved multi-dose psilocybin trial in Canada. Its results, together with the Health Canada special access program (SAP), are enabling psilocybin to be prescribed by physicians on a case-by-case basis to patients in need. To date, Braxia has treated patients with psilocybin through its ongoing multi-dose clinical trial and trained 20 therapists via the Braxia Institute for psilocybin-assisted therapy.
正在進行的試驗是加拿大第一個獲得批准的多劑量裸蓋菇素試驗。它的結果,連同加拿大衞生部特別訪問計劃(SAP),正在啟用裸蓋菇素將由醫生根據具體情況給患者開出在需要的時候。到目前為止,Braxia已經通過其正在進行的多劑量臨牀試驗治療了裸蓋菇素患者,並通過布拉夏裸蓋菇素輔助治療研究所.
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧